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Abstract
The prevalence of heart failure (HF) is increasing in patients with type 2 diabetes (T2D), and glucose-lowering agents have distinctive 
effects on the risk of developing HF that requires hospitalization. Such an increased risk has been consistently reported with thiazolidinediones 
(glitazones) and perhaps also with the dipeptidyl peptidase (DPP)-4 inhibitor saxagliptin (at least in SAVOR – TIMI 53), whereas a markedly 
decreased risk was highlighted with the sodium – glucose cotransporter type 2 (SGLT2) inhibitor empagliflozin in EMPA-REG OUTCOME. 
Yet, the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on myocardial function remain controversial. Whereas some 
promising observations have been reported in various animal models, the effects of GLP-1RAs on myocardial function in humans are 
more heterogeneous, while the positive effect on left ventricular ejection fraction (LVEF), if any, appears to be inconsistent and rather 
modest in most patients with HF. However, no increased risk of hospitalization for HF has been reported with GLP-1RAs in meta-analyses 
of phase-II/III trials (exenatide, albiglutide, dulaglutide, liraglutide), demonstrating the safety of this pharmacological class, and such 
findings have been confirmed by three large prospective cardiovascular outcome trials (ELIXA with lixisenatide, LEADER with liraglutide 
and SUSTAIN-6 with semaglutide). In particular, LEADER reported a trend towards a reduction in HF hospitalization (-13%, P = 0.14), 
together with a significant reduction in cardiovascular and all-cause mortality in patients with T2D at risk of cardiovascular disease. These 
results are reassuring in the face of the somewhat negative results of the FIGHT trial, which evaluated the effects of liraglutide in patients 
with advanced HF and low LVEF, such that further studies and caution are now required when using this agent to treat such patients in 
clinical practice. 
© 2017. Elsevier Masson SAS. All rights reserved
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1. Introduction
Both the increasing number of older patients with type 
2 diabetes (T2D) and improved survival of diabetic patients 
with acute coronary syndrome have resulted in a massive 
increase in patients with both T2D and heart failure (HF). It is 
also noteworthy that, besides advanced age, all the major risk 
factors for HF are clustered in patients with T2D, including 
obesity, hypertension, sleep apnoea, coronary heart disease 
and chronic kidney disease [1]. Therefore, the precise role 
of hyperglycaemia in the development of cardiovascular 
disease in general, and HF in particular, in patients with T2D 
remains controversial [2]. Diabetes may also cause cardiac 
dysfunction in the absence of overt macrovascular disease due 
to hyperglycaemia-related cardiomyopathy, even in patients 
in type 1 diabetes [3]. HF is of major interest as it is the one 
cardiovascular outcome for which the risk has unequivo-
cally been shown to be increased by some glucose-lowering 
therapies, particularly thiazolidinediones (glitazones) [4,5], 
whereas metformin appears to be safe [6]. Recently, some 
concerns have also been raised with the dipeptidyl peptidase 
(DPP)-4 inhibitor saxagliptin, following the publication of 
the Saxagliptin Assessment of Vascular Outcomes Recorded 
in Patients with Diabetes Mellitus (SAVOR) – Thrombolysis 
in Myocardial Infarction (TIMI) 53 trial [7], a finding that 
casts some suspicion on the entire incretin-based pharma-
cological class [8–10]. In contrast, a marked, significant 
reduction in hospitalizations for HF has been reported with 
the sodium – glucose cotransporter type 2 (SGLT2) inhibitor 
empagliflozin in the Empagliflozin Cardiovascular Outcome 
Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG 
OUTCOME) [11,12]. Because hospital admission for HF is 
a common and serious factor associated with a higher risk 
of death, HF is a cardiovascular outcome that can no longer 
be ignored in diabetic patients, especially when choosing a 
glucose-lowering agent [13]. 
Incretin-based therapies, including oral DPP-4 inhibitors 
and injectable glucagon-like peptide-1 receptor agonists 
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(GLP-1RAs), are increasingly being used for the management 
of T2D [14]. During recent years following the request of the 
US Food and Drug Administration (FDA), special attention 
has been focused on their cardiovascular effects [15–18], 
and greater concerns surfaced after the report of a higher 
incidence of hospitalization for HF with the DPP-4 inhibitor 
saxagliptin [7,8]. 
Thus, the primary objective of the present review is to 
succinctly discuss the effects of GLP-1RAs on cardiac func-
tion, focusing only on human studies to be concise. Recent 
reviews have summarized animal data in both ischaemic and 
reperfused myocardium, and in other conditions associated 
with myocardial remodelling and HF, as well as the results 
of experimental studies, and all have contributed to a better 
understanding of the molecular mechanisms and intracellular 
pathways involved in the myocardial protection induced by 
GLP-1 [15,19,20]. In addition, other reviews have focused on 
the effects of GLP-1RAs on biomarkers and cardiovascular 
risk factors [21,22]. Overall, the available set of data seems 
to suggest that GLP-1 analogues mimicking the action of 
endogenous GLP-1 could be considered a novel therapeutic 
strategy in diabetic patients with cardiovascular disease and 
HF [23]. The second review objective is to analyze the results 
of clinical trials that have investigated the effects of different 
GLP-1RAs on the risk of HF, especially the risk of hospitaliza-
tion for HF, in patients with T2D. As most of the studies of 
patients with or at risk of HF have involved liraglutide, a 
special place has been reserved for this GLP-1RA, which 
was evaluated in the large-scale Liraglutide Effect and Action 
in Diabetes: Evaluation of Cardiovascular Outcome Results 
(LEADER) trial [24].
2. GLP-1 and cardiac function
Following an initial open-label pilot study of GLP-1 treat-
ment of myocardial function in patients with T2D and HF [25], 
a few controlled trials have been performed, but mostly in 
a limited number of patients with a left ventricular ejection 
fraction (LVEF) < 40%. Mild improvements were observed 
in some studies [26,27], whereas no significant changes in 
LVEF were noted in others [28,29] (Table 1).
Similar mitigating results were reported with an infusion of 
exenatide (0.12 pmol/kg/min for 6 h) in 20 T2D patients with 
HF and LVEF ≤ 35% vs saline infusion in a crossover trial [30]. 
A significant increase in cardiac output was observed, mainly 
due to a significant increase in heart rate, but stroke volume 
remained almost unchanged with exenatide vs saline [30].
All these results have been summarized in a meta-analysis 
dedicated to the effects of GLP-1RAs in HF [31]. Its conclusion 
was that the use of GLP-1RAs has, at best, only a modest 
effect on LVEF improvement in patients with congestive heart 
failure [CHF; +4.4%, 95% confidence interval (CI): 1.36–7.44; 
P = 0.005 vs placebo], with no significant improvements in 
brain natriuretic peptide (BNP) levels. However, the small 
number of studies, the limited number of subjects in each trial, 
and the variations in dosage and duration of therapy among 
the trials somewhat limit these conclusions [31]. 
In addition, a recent study performed in T2D patients with 
HF (New York Heart Association II or III) and LVEF < 40% 
showed that treatment with the new GLP-1RA albiglutide 
(30 mg once a week for 12 weeks) compared with a placebo 
did not significantly improve LVEF, the 6-min walk test, or 
myocardial glucose or oxygen use [32].
3. GLP-1RAs and heart failure risk
The effects of GLP-1RAs on the risk of developing HF 
in patients with T2D have been analyzed by two large meta-
analyses of phase-II/III randomized controlled trials (RCTs; 
Table 2) [33,34]. The first meta-analysis provided data for all 
the GLP-1RAs combined and for each individual GLP-1RA 
(albiglutide, dulaglutide, exenatide and liraglutide) [33]. 
When considering all 20 pooled trials, the risk of HF was 
lower with GLP-1RAs than with the comparators [hazard 
Table 1
Effects of glucagon-like peptide (GLP)-1 intravenous infusion on left ventricular ejection fraction (LVEF) in patients with or without diabetes and heart 
failure





Thrainsdottir et al., 
2004 [25]
6 vs 0 (pilot) CHF
LVEF < 40%
72 h/3–4 Trend towards slight 
improvement
NS
Nikolaidis et al., 
2004 [26]
10 vs 11 Acute MI
LVEF < 40%
72 h /1.5 + 9 < 0.01
Sokos et al., 
2006 [27]
12 vs 9 CHF
LVEF ≤ 40%
5 weeks/2.5 + 5 < 0.001
Sokos et al., 
2007 [28]
10 vs 10 CABG without CHF*
LVEF > 40%
60 h/1.5 + 1 NS
Halbirk et al., 
2010 [29]
15 vs 15 CHF
LVEF < 40%
48 h/1.0 + 2 NS
* The only study with preserved LVEF;
CHF: congestive heart failure; MI: myocardial infarction; CABG: coronary artery bypass graft; NS: non-significant
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were similar for both DPP-4 inhibitors and GLP-1 analogues. 
For purposes of comparisons, the results of the incidence of 
hospitalization for HF with GLP-1RAs may be summarized 
as follows: patients with an HF history: 231/23,205 (1.0%) 
in case patients vs 4120/435,777 (0.9%) in controls (HR: 
0.95, 95% CI: 0.83–1.10); and patients with no HF history: 
35/6536 (0.5%) in case patients vs 743/100,480 (0.7%) in 
controls (HR: 0.75, 95% CI: 0.22–2.51). The duration of 
treatment with GLP-1RAs (< 1 year, 1–2 years, > 2 years) 
did not alter these results. Thus, in this analysis of data from 
large cohorts of patients with diabetes, GLP-1RAs were not 
associated with any increased risk of hospitalization for HF 
compared with the commonly used combinations of oral 
antidiabetic drugs [39].
4. Effects of liraglutide on cardiac function  
and cardiovascular events in HF patients
Several studies have investigated the effects of liraglutide on 
cardiac function in patients with or without diabetes, and with 
either coronary heart disease (with preserved LVEF) [40–42] 
or CHF and reduced LVEF (< 40%) [43–45]. The results 
were widely heterogeneous. Indeed, three studies reported 
a significant increase in LVEF in patients with preserved 
LVEF [40,41] and reduced LVEF [43], whereas three other 
studies – one in patients with preserved cardiac function [42] 
and two in patients with altered function [44,45] – reported 
almost no changes in LVEF with liraglutide compared with 
a placebo (Table 3). The two largest trials, with follow-ups 
of about 6 months, also reported virtually no changes in 
LVEF [44,45]. Thus, it may be concluded that the effect of 
liraglutide on LVEF is, if anything, modest and probably not 
clinically relevant.
ratio (HR): 0.62, 95% CI: 0.31–1.02]. Subgroup analyses 
of HF risk with each individual GLP-1RA suggested a 
possible differential treatment effect across individual agents 
(P = 0.07 for interaction), with liraglutide associated with 
a non-significant increased risk of HF [odds ratio (OR): 
4.85, 95% CI: 0.75–31.36]; this finding was, however, based 
on a limited number of events (five in total) and a very 
wide CI [33]. Nevertheless, these data were confirmed in 
the second meta-analysis reporting the HR for exenatide, 
albiglutide and liraglutide (Table 2) [34]. In two other meta-
analyses specifically dedicated to either albiglutide [35] or 
dulaglutide [36], neither reported any significantly increased 
risk of hospitalization for HF (Table 2). 
All these data confirm the cardiovascular safety of 
GLP-1RAs [37]. Indeed, these meta-analyses of RCTs with 
GLP-1RAs may be compared with those of RCTs with DPP-4 
inhibitors [9,10], which showed that DPP-4 inhibitors were not 
associated with any increased risk of HF-related hospitaliza-
tions [10] except for saxagliptin [9], mainly because of the 
results of the SAVOR – TIMI 53 trial [7].
In a retrospective cohort study of members of a large US 
health system, only one subject treated with GLP-1RAs was 
hospitalized for HF, making comparison with the controls 
impossible. Those treated with GLP-1RAs had lower risks 
of all-cause hospitalization (HR: 0.17, 95% CI: 0.02–1.23; 
P = 0.079) and all-cause death (HR: 0.17, 95% CI: 0.02–1.22; 
P = 0.078), although these estimates did not reach statisti-
cal significance [38]. In addition, healthcare data from four 
Canadian provinces, the US and the UK were used for a nested 
case – control analysis [39]. The cohorts included a total of 
1,499,650 patients, with 29,741 hospitalized for HF. These 
rates did not increase with the use of incretin-based drugs 
compared with other oral antidiabetic agents, and the results 
Table 2
Effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on risk of developing heart failure (HF) in patients with type 2 diabetes: meta-analyses 
of phase-II/III randomized controlled trials





Li et al., 2016 [33] All 20 17/7441 19/4317 0.62 (0.31–1.02)
Albiglutide 5 5/1427 11/1293 0.39 (0.14–1.07)
Dulaglutide 4 5/2231 2/967 1.12 (0.22–5.61)
Exenatide 5 2/991 4/842 0.51 (0.10–2.54)
Liraglutide 5 5/2298 0/1099 4.85 (0.75–31.36)
Wang et al., 
2016 [34]
Exenatide 5 4/1392 2/1371 1.92 (0.39–9.50)
Liraglutide 3 5/1361 0/748 5.52 (0.90–33.95)
Albiglutide 5 6/1427 12/1293 0.45 (0.17–1.17)
Fisher et al., 2016 
[35]
Albiglutide 8* 14/2424 11/2583 1.36 (NA)
Ferdinand et al., 
2016 [36]
Dulaglutide 9* 7/3885 2/2125 2.02 (0.41–9.88)
* Hospitalization for heart failure;
OR: odds ratio; CI: confidence interval; NA: not available
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These findings are expected to be confirmed by the 
Liraglutide in Young Adults with Type 2 Diabetes (LYDIA), 
a prospective randomized, open-label, active-comparator (vs 
sitagliptin) trial. The study will comprehensively describe 
changes in various parameters of cardiac structure and function 
in patients treated with liraglutide to provide new evidence of 
the effects of liraglutide on diastolic function in young obese 
patients with T2D [46].
The Functional Impact of GLP-1 for Heart Failure 
Treatment (FIGHT) study has tested the hypothesis that 
sustained therapy with liraglutide (up-titrated to 1.8 mg), 
initiated within 14 days of hospitalization for an acute HF 
syndrome (despite already receiving evidence-based therapies, 
including furosemide), is associated with greater clinical 
stability throughout 180 days in patients with or without T2D, 
and with advanced HF and reduced LVEF (≤ 40%) [45]. The 
primary endpoint was a global score in which patients were 
ranked across three hierarchical tiers: time to death; time to 
rehospitalization for HF; and time-averaged proportional 
change in N-terminal pro-BNP levels from baseline to 180 
days. Compared with placebo, liraglutide had no significant 
effect on the primary endpoint (mean rank score of 146 for 
the liraglutide group vs 156 for the placebo group; P = 0.31). 
There were also no significant between-group differences in 
number of deaths (HR: 1.10, 95% CI: 0.57–2.14; P = 0.78) 
or rehospitalizations for HF, whereas a trend towards higher 
risk was noted (HR: 1.30, 95% CI: 0.89–1.88; P = 0.17). 
Similarly, no significant between-group differences were 
reported for the different exploratory secondary endpoints 
(primary endpoint components plus cardiac structure and 
function, 6-min walk test, quality of life and combined 
events). In addition, prespecified subgroup analyses restricted 
to only patients with T2D failed to reveal any significant 
Table 3
Effects of liraglutide (titrated up to 1.8 mg/day) vs placebo on left ventricular ejection fraction (LVEF) in patients with coronary heart disease or 
congestive heart failure
Reference Liraglutide vs 
placebo (n)
Patient characteristics Treatment duration
(weeks)
Mean LVEF change % (95% 
CI)
P 
Patients with coronary heart disease (CHD) and preserved LVEF
Chen et al., 2015 [40] 45 vs 47 STEMI + PCI
LVEF > 40%
1a +4.1 (+1.1, +6.9) < 0.001
Chen et al., 2016 [41] 45 vs 45 Non-STEMI
LVEF > 40%
1a +4.7 (+0.7, +9.2) 0.009
Kamarathurai et al., 
2016 [42]
17 vs 13 CHD 
LVEF > 40%
12 +0.54 (-2.38, +3.45) 0.710
Patients with congestive heart failure and reduced LVEF
Margulies et al., 
2016 [45]
154 vs 146 LVEF ≤ 40% 26 +1.1 (-0.7, +2.8) 0.95
Jorsal et al., 2017 [44] 122 vs 119 LVEF ≤ 45% 24 – 0.8 (-2.1, +0.5) 0.24
Arturi et al., 2016 [43] 10 vs 10b LVEF < 45% 52 + 4.1 (NA) < 0.001
Data are mean placebo-subtracted changes vs baseline;
a 1-week treatment only, but evaluated after 12 weeks; b vs sitagliptin, not placebo;
STEMI: ST-segment elevation myocardial infarction; PCI: percutaneous coronary intervention; NA: not available
between-group differences [45]. Thus, in patients recently 
hospitalized for HF and a reduced LVEF, the use of liraglutide 
did not lead to greater post-hospitalization clinical stability. 
Thus, these findings do not support the use of liraglutide in 
such a clinical situation.
5. Lessons from LEADER
In this double-blind trial, patients with T2D and high 
cardiovascular risk were randomly assigned to receive 
liraglutide titrated up to 1.8 mg once daily (n = 4668) or 
placebo (n = 4672) [24]. The primary composite outcome in 
the time-to-event analysis was the first occurrence of death 
from cardiovascular causes, non-fatal myocardial infarction 
or non-fatal stroke. Hospitalization for HF was part of a 
prespecified exploratory outcome involving an expanded 
composite cardiovascular outcome. 
The primary outcome was observed in significantly fewer 
patients in the liraglutide group (608 of 4668 patients, 13.0%) 
than in the placebo group (694 of 4672, 14.9%; HR: 0.87, 
95% CI: 0.78–0.97; P = 0.01 for superiority). Fewer patients 
died due to either cardiovascular causes (HR: 0.78, 95% 
CI: 0.66–0.93; P = 0.007) or any cause (HR: 0.85, 95% CI: 
0.74–0.97; P = 0.02) in the liraglutide group than in the 
placebo group, with a trend towards a lower incidence of 
non-fatal myocardial infarction and non-fatal stroke. The 
reduction in the composite primary cardiovascular outcome 
did not differ significantly between subjects, whether with 
(n = 1305; HR: 0.94, 95% CI: 0.72–1.21) or without (n = 8035; 
HR: 0.85, 95% CI: 0.76–0.96) HF at baseline (P = 0.53 for 
interaction). Interestingly, there were fewer hospitalizations 
for HF (-13%; P = 0.14) among patients with liraglutide than 
with the placebo, although the difference was not significant 
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(Table 4) [24]. It should be noted, however, that hospitalization 
for HF was only part of the prespecified exploratory, expanded, 
composite cardiovascular outcome of LEADER, as well as 
other RCTs, in patients with T2D and high cardiovascular risk. 
As previously discussed [13], the universal lack of large-scale 
trials of the use of the new glucose-lowering drugs for hospital 
admissions for HF as a prespecified component of the primary 
composite cardiovascular outcome is a major concern, given 
the high prevalence and seriousness of this situation among 
T2D patients.
In fact, the lack of any significant difference in the risk of 
hospitalizations for HF between those treated with a GLP-1RA 
or a placebo reported with liraglutide in LEADER [24] was 
confirmed with lixisenatide in the Evaluation of Lixisenatide 
in Acute Coronary Syndrome (ELIXA) trial [47] and with 
semaglutide in the Trial to Evaluate Cardiovascular and Other 
Long-term Outcomes with Semaglutide in Subjects with 
Type 2 Diabetes (SUSTAIN-6; Table 4) [48]. Unfortunately, 
no measurements of pro-BNP levels were available in the 
LEADER trial [24], and this key information was also missing 
in the ELIXA [47] and SUSTAIN-6 [48]. However, such 
measurements were included in two trials of DPP-4 inhibitors: 
the EXAMINE with alogliptin [49]; and SAVOR – TIMI 53 
with saxagliptin [50]. In EXAMINE, alogliptin had no effect 
on the composite events of cardiovascular death and hospital 
admission for HF on post-hoc analysis (HR: 1.00, 95% CI: 
0.82–1.21), and the results did not differ by baseline BNP 
concentration [49]. In SAVOR – TIMI 53, the increased risk 
of hospitalization for HF was highest among patients with 
elevated levels of natriuretic peptides, previous HF or chronic 
kidney disease [50].
Thus, the LEADER trial demonstrated that liragutide can 
reduce cardiovascular and all-cause mortality in T2D patients 
at high cardiovascular risk. The underlying mechanisms of this 
protection, however, remain largely unexplained, although the 
contributions of both indirect systemic and direct myocardial 
effects have been postulated [22]. In general, though, these 
protective mechanisms seem to differ from those proposed 
for empagliflozin in EMPA-REG OUTCOME [11], for which 
various explanations have also been put forward, yet is still 
Table 4









































ELIXA: Evaluation of Lixisenatide in Acute Coronary Syndrome; LEADER: Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; 
SUSTAIN-6: Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes
controversial [51]. One marked difference between LEADER 
and EMPA-REG OUTCOME is the distinctive outcome of a 
35% (P < 0.001) reduction in hospitalizations for HF reported 
with empagliflozin, whereas only a slight, non-significant reduc-
tion was noted with liraglutide (-13%, P = 0.14; Table 4). Both 
liraglutide and empagliflozin reduce systolic blood pressure, an 
independent risk factor of HF, but the insignificant difference 
vs the placebo arm in T2D patients with blood pressure already 
well controlled at baseline cannot explain the marked reduction 
in hospitalizations for HF in the EMPA-REG OUTCOME [52]. 
As the placebo-subtracted difference in systolic blood pressure 
was lower in LEADER than in EMPA-REG OUTCOME, any 
crucial role of blood-pressure reduction with liraglutide can most 
likely also be excluded. The difference between the results of 
these two trials regarding the effects on HF could be explained 
by the specific mechanism of action of the SGLT2 inhibitor 
targeting the kidneys and its related diuretic effect [53]. In any 
case, the LEADER trial has demonstrated the safe use of the 
GLP-1RA liraglutide in patients at high cardiovascular risk with 
no increased incidence of HF. Nevertheless, given the negative 
results of the FIGHT study [45], the use of liraglutide should 
be recommended with caution in patients with advanced HF 
and reduced LVEF, and further studies are now also required 
in this particular patient population.
6. Conclusion
HF is an increasingly common complication among 
patients with T2D, and the various glucose-lowering agents 
used in the management of T2D have distinctive effects on 
the risk of hospitalization for HF. Incretin-based therapies 
have been scrutinized, especially after the SAVOR – TIMI 
53 trial showed a significantly greater incidence of HF 
hospitalizations in T2D patients with antecedents of cardio-
vascular disease receiving saxagliptin vs placebo. However, 
this effect was not confirmed in other trials using different 
DPP-4 inhibitors. Yet, despite the promising preliminary 
results from animal models, in general, GLP-1RAs either do 
not, or only slightly and inconsistently, improve myocardial 
function in patients with coronary artery disease or HF with 
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decreased LVEF. The risk of hospitalization for HF was not 
increased in several meta-analyses of phase-II/III RCTs 
involving different GLP-1RAs, demonstrating the safety 
of compounds in this pharmacological class in this respect. 
However, an imbalance between the liraglutide and control 
arms was observed, although the number of events was too 
limited to allow any definite conclusions to be drawn. On 
the other hand, the large prospective LEADER RCT in 
patients at high risk of cardiovascular disease has provided 
reassuring data, with a trend towards a lower incidence of 
hospitalization for HF in the liraglutide arm compared with 
the placebo arm, together with a markedly significant reduc-
tion in cardiovascular and all-cause mortality. Nevertheless, 
the results of the FIGHT trial, including a non-significant 
trend for more rehospitalizations for HF in patients with 
advanced HF and decreased LVEF treated with liraglutide, 
demands caution and calls for further investigation. 
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